Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
Running, not enrolling · Phase 3
Conditions studied: HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
In brief
The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer.
Key facts
- Study ID
- NCT02947685
- Run by
- Alliance Foundation Trials, LLC.
- People needed
- 518
- Starts
- 2017-06-21
- Expected to finish
- 2026-07-31
- Last updated by the study team
- 2026-02-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Georgetown University Medical Center — Washington D.C., District of Columbia, United States
- Baycare Healthcare (Morton Plant Mease) — Clearwater, Florida, United States
- Memorial Healthcare System — Hollywood, Florida, United States
- University of Miami — Miami, Florida, United States
- Florida Hospital — Orlando, Florida, United States
- Emory University — Atlanta, Georgia, United States
- University of Illinois at Chicago — Chicago, Illinois, United States
- Ingalls Memorial Hospital — Harvey, Illinois, United States
- Cancer Center of Kansas — Wichita, Kansas, United States
- Ochsner Medical Center Jefferson — New Orleans, Louisiana, United States
- New England Cancer Specialists — Scarborough, Maine, United States
- University of Maryland - Greenebaum Comprehensive Cancer Center — Baltimore, Maryland, United States
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Lowell General Hospital — Lowell, Massachusetts, United States
- Michigan Cancer Research Consortium (St. Joseph Mercy Hospital — Ann Arbor, Michigan, United States
- West Michigan Cancer Center — Grand Rapids, Michigan, United States
- Metro-Minnesota NCI Community Oncology Research Program — Minneapolis, Minnesota, United States
- Mayo Clinic, Rochester, MN — Rochester, Minnesota, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Nebraska Methodist Hospital — Omaha, Nebraska, United States
- University of Nebraska Medical Center — Omaha, Nebraska, United States
- Hackensack Medical Center — Hackensack, New Jersey, United States
- The Valley Hospital, Okonite Research Center — Paramus, New Jersey, United States
- UCSF — San Francisco, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.